On Friday, Denali Therapeutics Inc (DNLI) stock saw a modest uptick, ending the day at $27.05 which represents a slight increase of $1.09 or 4.20% from the prior close of $25.96. The stock opened at ...

Jefferies raised the firm’s price target on Denali Therapeutics (DNLI) to $45 from $40 and keeps a Buy rating on the shares ahead of the ...

In a report released today, Michael Yee from Jefferies maintained a Buy rating on Denali Therapeutics (DNLI – Research Report), with a ...

Ryan J. Watts, President and CEO of Denali Therapeutics Inc. (NASDAQ:DNLI), recently sold 40,000 shares of the company's common stock. The shares were sold at an average price range of $27.49 to $ ...

Ryan J. Watts, President and CEO of Denali Therapeutics Inc. (NASDAQ:DNLI), recently sold 40,000 shares of the company's common stock. The shares were sold at an average price range of $27.49 to ...

Find Therapeutics logo (CNW Group/Find Therapeutics Inc.) The Phase 1 first-in-human study will assess the safety, tolerability, and pharmacokinetics of FTX-101 when administered in healthy ...

The pair climbed Denali and sampled microplastics along their route in June, 2024. (Photo by Roger Jaramillo) Two mountaineers who are also University of Alaska Fairbanks students were successful ...

Dr. Carole Ho, chief medical officer at neurological biotech Denali Therapeutics, sat down with Lauren to discuss what’s next for the Rare Disease Innovation Hub and the rare-disease community ...